Lowering HbA1c in type 2 diabetics results in reduced risk of coronary heart disease and all-cause mortality

References 

1. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004;141:421–431
2. The Diabetes Control and Complications Trial Research Group . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Eng. J. Med. 1993;329:977–986
3. UK Prospective Diabetes Study Group . Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–712
   • MEDLINE
   • CrossRef
4. The Dutch Cochrane Collaboration, Checklist “Cohort” and “SR-Obs”, 2003, www.cochrane.nl.
5. Levels of evidence: http://www.cebm.net/levels_of_evidence.asp#levels.
6. Selvin E, Marinopoulos S, Berkenblit G, et al. Meta analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann. Intern. Med. 2004;141:421–431
7. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin-dependent diabetes mellitus. The Finnish studies. Ann. Intern. Med. 1996;124:127–130
   • MEDLINE
8. Donnan PT, Donnelly L, New JP, Morris AD. Derivation and validation of a prediction score for major coronary heart disease events in a UK type 2 diabetic population. Diabetes Care. 2006;29:1231–1236
   • MEDLINE
   • CrossRef
9. Adler AI, Neil HA, Manley SE, et al. Hyperglycemia and hyperinsulinemia at diagnosis of diabetes and their association with subsequent cardiovascular disease in the United Kingdom prospective diabetes study (UKPDS 47). Am. Heart J. 1999;138:353–359
10. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
    • MEDLINE
    • CrossRef
11. Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49:1761–1769
    • MEDLINE
    • CrossRef
12. Selvin E, Coresh J, Golden SH, et al. Glycemic control and coronary heart disease risk in persons with and without diabetes. Arch. Intern. Med. 2005;165:1910–1916
    • MEDLINE
    • CrossRef
13. Kirkman MS, McCarren M, Shah J, et al. The association between metabolic control and prevalent macrovascular disease in type 2 diabetes: the VA cooperative study in diabetes. J. Diab. Compl. 2006;20:75–80
14. Standl E, Balletshofer B, Dahl B, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia. 1996;39:1540–1545
    • MEDLINE
    • CrossRef
15. Gerstein HC, Pogue J, Mann JF, et al. The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis. Diabetologia. 2005;48:1749–1755
    • MEDLINE
    • CrossRef
16. Massi-Benedetti M. Changing targets in the treatment of type 2 diabetes. Curr. Med. Res. Opin. 2006;22:S5–S13
    • CrossRef
17. American Diabetes Association . Standards of medical care in diabetes—2006. Diabetes Care. 2006;29(Suppl. 1):S4–S42
18. International Diabetes Federation Clinical Guidelines Taskforce, Global Guideline for Type 2 Diabetes, International Diabetes Federation, Brussels, 2005.
19. McIntosh A, Hutchinson A, Home PD, et al. Clinical Guidelines and Evidence Review for Type 2 Diabetes: Blood Glucose Management. Sheffield: ScHARR, University of Sheffield; 2001;
20. Rutten GEHM, de Grauw WJC, Nijpels G, Goudswaard AN, et al. Practice guideline diabetes mellitus type 2. Huisarts Wet. 2006;49:137–152